Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure

Biochemistry

Volumn 47, Issue 25, 2008, Pages 6662-6670

  Bai, Xuefang ^a   Wilson, Karen L ^a   Seedorff, Jennifer E ^a   Ahrens, Douglas ^a   Green, Justin ^a   Davison, Donna K ^a   Jin, Lei ^a   Stanfield Oakley, Sherry A ^a   Mosier, Sarah M ^a   Melby, Thomas E ^a   Cammack, Nick ^b   Wang, Zhongmin ^c   Greenberg, Michael L ^a   Dwyer, John J ^a  

^a Trimeris Inc   (United States)

^b Roche   (United States)

^c ZM Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMERICAN CHEMICAL SOCIETY (ACS); ANTIVIRAL ACTIVITIES; CIRCULAR DICHROISM (DC); CLINICAL USES; HELICITY; HELIX BUNDLES; HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1); IN-VITRO ASSAYS; ION PAIRS; LOSS OF STABILITY; MUTATION RESULTS; PEPTIDE MODELS; THERMAL STABILITY; VIRAL FITNESS; X RAY CRYSTALLOGRAPHY;

AMINES; CRYSTALLOGRAPHY; DATA FUSION; DICHROISM; FUSION REACTIONS; HEALTH; IMPACT RESISTANCE; MATHEMATICAL MODELS; MICROFLUIDICS; MINERALOGY; NUCLEAR PHYSICS; OPTICAL PROPERTIES; POLYMORPHISM; SYSTEM STABILITY; THERMODYNAMIC STABILITY; WEIGHT CONTROL; X RAY CRYSTALLOGRAPHY;

ANIMAL CELL CULTURE;

ENFUVIRTIDE; GLYCOPROTEIN GP 41; PEPTIDE;

ARTICLE; CIRCULAR DICHROISM; DRUG SENSITIVITY; GENETIC ASSOCIATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; THERMOSTABILITY; VIRUS MUTATION; VIRUS RESISTANCE; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CIRCULAR DICHROISM; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; HYDROGEN BONDING; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MUTATION; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 45749147766     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi702509d     Document Type: Article

References (36)

1. Wild, C., Oas, T., McDanal, C., Bolognesi, D., and Matthews, T. (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. U.S.A. 89, 10537-10541.
2. Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., and Matthews, T. J. (1994) Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U.S.A. 91, 9770-9774.
3. Rimsky, L. T., Shugars, D. C., and Matthews, T. J. (1998) Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72, 986-993.
4. Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Zhang, Z., O'Brien, W. A., Ratner, L., Shaw, G. M., and Hunter, E. (2001) Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75, 8605-8614.
5. Greenberg, M. L., and Cammack, N. (2004) Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 54, 333-340.
6. Sista, P. R., Melby, T., Davison, D., Jin, L., Mosier, S., Mink, M., Nelson, E. L., DeMasi, R., Cammack, N., Salgo, M. P., Matthews, T. J., and Greenberg, M. L. (2004) Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 18, 1787-1794.
7. Menzo, S., Castagna, A., Monachetti, A., Hasson, H., Danise, A., Carini, E., Bagnarelli, P., Lazzarin, A., and Clementi, M. (2004) Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob. Agents Chemother. 48, 3253-3259.
8. Melby, T., Sista, P., DeMasi, R., Kirkland, T., Roberts, N., Salgo, M., Heilek-Snyder, G., Cammack, N., Matthews, T. J., and Greenberg, M. L. (2006) Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res. Hum. Retroviruses 22, 375-385.
9. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., and Kappesa, J. C. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46, 1896-1905.
10. Mink, M., Mosier, S. M., Janumpalli, S., Davison, D., Jin, L., Melby, T., Sista, P., Erickson, J., Lambert, D., Stanfield-Oakley, S. A., Salgo, M., Cammack, N., Matthews, T., and Greenberg, M. L. (2005) Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J. Virol. 79, 12447-12454.
11. Lu, J., Sista, P., Giguel, F., Greenberg, M., and Kuritzkes, D. R. (2004) Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 78, 4628-4637.
12. Reeves, J. D., Lee, F.-H., Miamidian, J. L., Jabara, C. B., Juntilla, M. M., and Doms, R. W. (2005) Enfuvirtide resistance mutations: Impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 79, 4991-4999.
13. Aquaro, S., D'Arrigo, R., Svicher, V., Di Perri, G., Lo Caputo, S., Visco-Comandini, U., Santoro, M., Bertoli, A., Mazzotta, F., Bonora, S., Tozzi, V., Bellagamba, R., Zaccarelli, M., Narciso, P., Antinori, A., and Perno, C. F. (2006) Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. J. Antimicrob. Chemother. 58, 714-722.
14. Melby, T., DeSpirito, M., DeMasi, R., Heilek, G., Thommes, J. A., Greenberg, M. L., and Graham, N. (2007) Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy. AIDS 21, 2537-2539.
15. Xu, L., Pozniak, A., Wildfire, A., Stanfield-Oakley, S. A., Mosier, S. M., Ratcliffe, D., Workman, J., Joall, A., Myers, R., Smit, E., Cane, P. A., Greenberg, M. L., and Pillay, D. (2005) Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 49, 1113-1119.
16. Cabrera, C., Marfil, S., Garcia, E., Martinez-Picado, J., Bonjoch, A., Bofill, M., Moreno, S., Ribera, E., Domingo, P., Clotet, B., and Ruiz, L. (2006) Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. AIDS 20, 2075-2080.
17. Lalezari, J. P., DeJesus, E., Northfelt, D. W., Richmond, G., Wolfe, P., Haubrich, R., Henry, D., Powderly, W., Becker, S., Thompson, M., Valentine, F., Wright, D., Carlson, M., Riddler, S., Haas, F. F., DeMasi, R., Sista, P. R., Salgo, M., and Delehanty, J. (2003) A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antiviral Ther. 8, 279-287.
18. Tolstrup, M., Selzer-Plon, J., Laursen, A. L., Bertelsen, L., Gerstoft, J., Duch, M., Pedersen, F., and Ostergaard, L. (2007) Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K). AIDS 21, 519-521.
19. Cao, J., Bergeron, L., Helseth, E., Thali, M., Repke, H., and Sodroski, J. (1993) Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 67, 2747-2755.
20. Lu, M., Stoller, M. O., Wang, S., Liu, J., Fagan, M. B., and Nunberg, J. H. (2001) Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J. Virol. 75, 11146-11156.
21. Weng, Y., and Weiss, C. D. (1998) Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J. Virol. 72, 9676-9682.
22. Follis, K. E., Larson, S. J., Lu, M., and Nunberg, J. H. (2002) Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state. J. Virol. 76, 7356-7362.
23. Suntoke, T. R., and Chan, D. C. (2005) The fusion activity of HIV-1 gp41 depends on interhelical interactions. J. Biol. Chem. 280, 19852-19857.
24. Tan, K., Liu, J., Wang, J., Shen, S., and Lu, M. (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. U.S.A. 94, 12303-12308.
25. Malashkevich, V. N., Chan, D. C., Chutkowski, C. T., and Kim, P. S. (1998) Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: Conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc. Natl. Acad. Sci. U.S.A. 95, 9134-9139.
26. Dwyer, J. J., Wilson, K. L., Davison, D., Freel, S. A., Seedorff, J. E., Wring, A. A., Tvermoes, N. A., Matthews, T. J., Greenberg, M. L., and Delmedico, M. K. (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistance virus. Proc. Natl. Acad. Sci. U.S.A. 104, 12772-12777.
27. Hu, Q. X., Barry, A. P., Wang, Z. X., Connolly, S. M., Peiper, S. C., and Greenberg, M. L. (2000) Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 74, 11858-11872.
28. Kimpton, J., and Emerman, M. (1992) Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66, 2232-2239.
29. Edelhoch, H. (1967) Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6, 1948-1954.
30. Johnson, W. C. (1990) Protein secondary structure and circular dichroism: A practical guide. Proteins: Struct., Funct., Genet. 7, 205-214.
31. Dwyer, J. J., Hasan, A., Wilson, K. L., White, J. M., Matthews, T. J., and Delmedico, M. K. (2003) The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 42, 4945-4953.
32. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., and Wiley, D. C. (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430.
33. Chan, D. C., Fass, D., Berger, J. M., and Kim, P. S. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273.
34. Labrosse, B., Morand-Joubert, L., Goubard, A., Rochas, S., Labernardiere, J. L., Pacanowski, J., Meynard, J. L., Hance, A. J., Gavel, F., and Mammano, F. (2006) Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J. Virol. 80, 8807-8819.
35. DeLano, W. L. (2002) The PyMOL Molecular Graphics System, version 0.92, DeLano Scientific, San Carlos, CA.
36. Deeks, S. G., Lu, J., Hoh, R., Neilands, T. B., Beatty, G., Huang, W., Liegler, T., Hunt, P., Martin, J. N., and Kuritzkes, D. R. (2007) Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J. Infect. Dis. 195, 318-321.